| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6199933 | Ophthalmology | 2014 | 8 Pages |
Abstract
There was no statistically significant difference in corticosteroid-sparing control of inflammation between patients receiving methotrexate or mycophenolate mofetil. However, there was a 22% difference in treatment success favoring methotrexate.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Sivakumar R. MD, PhD, Manohar MD, Radhika MD, Anuradha MD, Natalie PhD, Elizabeth MS, Salena M. OD, Wayne T.A. PhD, MPH, Travis C. PhD, MPH, Erica N. MS, Rachel MPH, Nisha R. MD, MS,